Etudes cliniques en cours

Découvrez ici la liste des différentes études cliniques en cours classées par centre.

CHU Liège

  • Neodjuvant/adjuvant
    NSCLC resectable Iib/IIIa
    MK3475-671
    Platinum doublet chemotherapy ± pembrolizumab
  • 1-2LM
    NSCLC Squameux/non-squameux
    CANFOUR
    • Cisplatine/gemcytabine + CAN 04
    • CAN04 seul
  • NSCLC
    Slots variables
    GCT1021 -01
    Humax-AXL-ADC
  • NSCLC
    Slots variables
    CNIR
    PDR001 + NIR178
  • adjuvant
    NSCLC RO
    GO39733
    Atezolizumab + vaccin personnalisé
  • NSCLC
    Slots variables
    Pivot 02
    Nektar-IL2 + nivo Q3W

CHU Mont-Godinne

Etudes sponsorisées interventionnelles en cours:

  • PEARLS: A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy.
  • Intr@pid: A Phase II, Multicenter, Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Nonsmall Cell Lung Cancer.

Etudes sponsorisées non interventionnelles en cours:

  • BEPACT Lung: Impact of Patient Characteristics on pneumo-oncologists NSCLC systemic treatment decision in Belgium: A cross-sectional study.

Etudes académiques non interventionnelles en cours:

  • ELCWP: Cardiovascular morbidities and lung cancer treatment: a prospective registry.

Cliniques Universitaires Saint-Luc

1st line

  • BO29554 study (B-FAST)
    A phase II/III multicentre study evaluating the efficacy and safety of multiple targeted therapies as treatments for patients with advanced or metastatic non-small cell lung cancer (NSCLC) harbouring actionable somatic mutations detected in blood (B-Fast: blood-first assay screening trial)
  • ADRIATIC (D933QC00001)
    Phase III, randomised, double-blind, placebo-controlled, multi-centre study assessing the efficacy and safety of durvalumab or durvalumab and tremelimumab in patients with LD-SCLC who have not progressed following definitive, platinum-based, concurrent chemoradiation therapy (CRT)
  • Zenith20 (Spectrum) (SPI-POZ-202)
    A phase 2 study of poziotinib in patients with NSCLC, locally advanced or metastatic, with EGFR or HER2 exon insertion mutation

2nd/3rd line

  • CACZ885V2301
    A phase III, multicenter, 2parallel cohort, randomized, double-blind study evaluating the efficacy and safety of canakinumab in combination with docetaxel vs docetaxel alone given as second or third line therapy in adult patients with NSCLC previously treated with PD(L)1 inhibitors and platin-based chemotherapy

Autres

  • REVEAL D5161R00007
    REtrospective, obserVational study to describe the treatment patterns and outcomes of Epidermal Growth Factor Receptor mutant (EGFRm) locally Advanced or metastatic Non-Small-Cell Lung Cancer (NSCLC) patients in Belgium
  • BEPACT
    Impact of Patient Characteristics on pneumo-oncologists NSCLC systemic treatment decision in Belgium: A cross-sectional study
  • Radiomics
    Analyse Radiomique d’une cohorte de patients CPNPC traités par immunothérapie aux Cliniques Universitaire St-Luc : Un biomarqueur potentiel pour prédire et quantifier la réponse au traitement et les complications liés à l’immunothérapie
  • ANAM 17-21
    A phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to evaluate the efficacy and safety of Anamorelin HCl for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced NSCLC
  • EORTC: E2-Radiate 1811
    E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe

GHdC

PathologieNomTitrePhaseStatutPINumero Interne
Poumons et ThoraxANAM-17-21A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of anamorelin HCl for the treatment of malignancy associated
weight loss and anorexia in adult patients with advanced non-small cell lung cancer (NSCLC)
Phase 3Ouverte à l'inclusionColinet Benoît2018-ONCOHEMA-0228
Poumons et ThoraxPearlsA Randomized, Phase 3 Trial With Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) Versus Placebo for Patients With Early Stage NSCLC After Resection and Completion of Standard Adjuvant Therapy (PEARLS)Phase 3Ouverte à l'inclusionColinet Benoît2018-ONCOHEMA-0158
Poumons et ThoraxPACIFIC-4A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)Phase 3Ouverte à l'inclusionColinet Benoît2019-ONCOHEMA-0111
Poumons et ThoraxPDC-Lung-101An open-label, dose escalation phase I/II study assessing the safety and immunogenicity of PDC*lung, therapeutic cancer vaccine, as single agent or in combination with a checkpoint inhibitor, in patients with Non-Small Cell Lung Cancer (NSCLC) Phase 1
Phase 2
Ouverte à l'inclusionColinet Benoît2018-ONCOHEMA-0159
Poumons et ThoraxCanopy-2A phase III, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of canakinumab in combination with docetaxel vs placebo in combination with docetaxel in patients with non-small cell lung cancer (NSCLC) previously treated with PD(L)1 inhibitors and platin-based chemotherapyPhase 3Ouverte à l'inclusionColinet Benoît2018-ONCOHEMA-0184
Toutes TumeursDRIIV-1 / Phase Ib comboEtude de Phase I/Ib d’escalade de dose en ouvert destinée à évaluer la tolérance,la pharmacocinétique et la pharmacodynamique d’AsiDNATM, un inhibiteur de réparation de l’ADN administré par voie intraveineuse en monothérapie et à évaluer la tolérance et l'efficacité d'AsiDNA administré en association avec Carboplatine avec ou sans Paclitaxel chez des patients atteints de tumeurs solides à un stade avancé. Phase 1
Phase 1b
Ouverte à l'inclusionCanon Jean-Luc2019-ONCOHEMA-0047
Poumons et Thorax01151Cardiovascular morbidities and lung cancer treatment: a prospective registryObservationnelleOuverte à l'inclusionColinet Benoît2018-ONCOHEMA-0078
Poumons et ThoraxPacific RFirst real-world data study on Unresectable stage III NSCLC Patients treated with durvalumab within the Early Access Program (EAP) after chemoradiotherapyObservationnelleOuverte à l'inclusionColinet Benoît2018-ONCOHEMA-0216
Toutes TumeursTranslateTreatment resistance following anti-cancer therapiesProspective-Collection d'échantillonsOuverte à l'inclusionCanon Jean-Luc2018-ONCOHEMA-0205
Toutes TumeursTumorbaseProspective collection of biological samples for translational research on patients with tumoral or hematological diseases (TUMOR-base)Prospective-Collection d'échantillonsOuverte à l'inclusionCarrasco Javier2018-ONCOHEMA-0173
Poumons et Thorax20190294A non-interventional biomarker study on the molecular evaluation of archival tumor tissue in subjects with non-small cell lung cancerProspective-Collection d'échantillonsOuverture prochaineColinet Benoît2019-ONCOHEMA-0193

Login

Connectez-vous pour avoir accès au contenu privé.

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.

Ok